Looking To Learn From Past Failures, Galapagos Pivots To Immunology And CAR-T
200 Jobs Shed And Pipeline Cut Back
The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.
You may also be interested in...
Paul Stoffels On Galapagos’s Turnaround And Making Its Gilead Partnership Work
After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.
J.P. Morgan Day Two: Playing Up Potential In The Year Ahead
Daily notebook from the J.P. Morgan Healthcare Conference: Small and mid-size companies take the stage to lay out their guidance for the year, while big pharma is pushed on strategy and business development. Updates from GSK, Mirati, Sarepta, Amgen and US FDA commissioner Robert Califf.
Galapagos Enters Cancer Field With CellPoint Buy
Deal Snapshot: CEO Stoffels delivered on a recent promise to bring in mid-stage assets, acquiring a firm with a Phase I/IIa CAR-T therapy program for €125m ($131.6m) up front.